Navigation Links
Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
Date:5/14/2012

INDIANAPOLIS, May 14, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from several molecules that make up its clinical oncology pipeline during the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. from June 1 – 5, 2012.

Lilly Oncology has more than 30 molecules in early- and late-stage development to treat various types of cancer. The company remains committed to evaluating each of its molecules for biomarkers or genetic mutations that can help better identify the specific patients who will better respond to these medicines.  

Early-Stage Pipeline Results

Lilly early-stage pipeline molecules will be featured at oral presentations at ASCO with two first-in-human Phase I studies, one on its oral NOTCH inhibitor LY900009 and the other for its oral p38 MAPK inhibitor LY2228820 dimesylate, both being evaluated in patients with advanced cancer. Another oral presentation will highlight LY2780301, an oral P70S6K/AKT inhibitor, a first-in-human Phase I study of patients with refractory solid tumors.

Late-Stage Ramucirumab Updates

Lilly will also present several trials-in-progress posters representing a portion of the broad Phase III clinical development program for ramucirumab, a fully human IgG1 monoclonal antibody receptor antagonist designed to bind to the extracellular domain of vascular endothelial growth factor receptor-2 (VEGFR-2). Trial updates for ramucirumab will focus on its ongoing Phase III trials in metastatic colorectal cancer, metastatic gastric adenocarcinoma and hepatocellular cancer, as well as results of a Phase II study in persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.

Ramucirumab represents one of the largest clinical programs currently underway at Lilly. Six global Phase III trials – one each in breast, colorectal, hepatocellular and lung cancer, and two in gastric cancer – are ongoing and patient enrollment milestones have recently been achieved in both the Phase III breast and gastric (monotherapy) cancer trials.

"Lilly Oncology's clinical pipeline is one of the most diverse in the industry, including a mix of large and small molecules that target a broad range of cancers," said Richard Gaynor, M.D., vice president, product development and medical affairs for Lilly Oncology. "We believe that our broad oncology research and development program will lead to new therapies for a wide array of patients."

Times and Locations of the Data Sessions:

Ramucirumab (IMC-1121B)

  • Abstract #5012: Poster Session: Friday, June 1, 2012, 1:00 PM - 5:00 PM
    • A phase II, open-label, multicenter study of IMC-1121B (ramucirumab; RAM) monotherapy in the treatment of persistent or recurrent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal (PPC) carcinoma (CP12-0711/NCT00721162).
    • Author/Speaker: Richard T. Penson
    • Location: E450a; Poster Board 1
  • Abstract #TPS3634: Trials in Progress Poster Session: Monday, June 4, 2012, 8:00 AM - 12:00 PM
    • A randomized, double-blind, phase (Ph) III study of the irinotecan-based chemotherapy FOLFIRI plus ramucirumab (RAM) or placebo (PL) in patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (RAISE) (NCT01183780).
    • Author/Speaker: Axel Grothey
    • Location: S Hall A2; Poster Board 38G
  • Abstract #TPS4139: Trials in Progress Poster Session: Monday, June 4, 2012, 8:00 AM - 12:00 PM
    • A randomized, multicenter, double-blind, placebo (PBO)-controlled phase III study of paclitaxel (PTX) with or without ramucirumab (IMC-1121B; RAM) in patients (pts) with metastatic gastric adenocarcinoma, refractory to or progressive after first-line therapy with platinum (PLT) and fluoropyrimidine (FP).
    • Author/Speaker: Hansjochen Wilke
    • Location: S Hall A2; Poster Board 53B
  • Abstract #TPS4146: Trials in Progress Poster Session: Monday, June 4, 2012, 8:00 AM - 12:00 PM
    • A multicenter, randomized, double-blind, phase III study of ramucirumab (IMC-1121B; RAM) and best supportive care (BSC) versus placebo (PBO) and BSC as second-line treatment in patients (pts) with hepatocellular carcinoma (HCC) following first-line therapy with sorafenib (SOR).
    • Author/Speaker: Andrew X. Zhu
    • Location: S Hall A2; Poster Board 54A

NOTCH inhibitor (LY900009)

  • Abstract #3008: Oral Abstract Session: Sunday, June 3, 2012, 12:15 PM - 12:30 PM
    • A first-in-human phase I study of the oral Notch inhibitor LY900009 in patients with advanced cancer
    • Author/Speaker: Shubham Pant
    • Location: E Arie Crown Theater

p38 MAPK inhibitor (LY2228820 dimesylate)

  • Abstract # 3001: Oral Abstract Session: Sunday, June 3, 2012, 10:00 AM – 10:15 AM
    • A first-in-human phase I study of the oral p38 MAPK inhibitor LY2228820 dimesylate in patients with advanced cancer.
    • Author/Speaker: Matthew P. Goetz
    • Location: E Arie Crown Theater

P70S6K/AKT inhibitor (LY2780301)

  • Abstract # 3005: Oral Abstract Session: Sunday, June 3, 2012, 11:15 AM – 11:30 AM
    • First-in-human phase I study of LY2780301, an oral P70S6K/AKT inhibitor, in patients with refractory solid tumors.
    • Author/Speaker: Emiliano Calvo
    • Location: E Arie Crown Theater

P-LLY

This press release contains forward-looking statements about the potential of ramucirumab, LY900009, LY2228820 dimesylate and LY2780301 and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that the products will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

(Logo:  http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
2. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
3. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
4. DiversityInc Names Lilly a Top Company for Diversity
5. Lilly Declares Second-Quarter 2012 Dividend
6. Lilly Diabetes and Walgreens Launch Diabetes Hypoglycemia Awareness Campaign
7. Lillys John Lechleiter Becomes PhRMA Board Chairman; Robert J. Hugin, Ian Read Assume New Posts
8. Lilly Confirms Date and Conference Call for First-Quarter 2012 Financial Results Announcement
9. Lilly Diabetes supports Diabetes Scholars Foundation with $100,000 donation in 2012
10. Fifth Lilly Oncology on Canvas Art Competition Invites All Touched by Cancer to Share Their Cancer Journeys
11. Boehringer Ingelheim and Lillys new oral type 2 diabetes treatment for adults, Jentadueto™ (linagliptin/metformin hydrochloride) tablets, now available in U.S. pharmacies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute Ischemic Stroke Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Ischemic Stroke Market and Competitive Landscape Highlights ... Stroke pipeline products, Acute Ischemic Stroke epidemiology, ...
(Date:5/3/2016)... PUNE, India , May 4, 2016 /PRNewswire/ ... report spreads across 154 pages, profiling 09 key ... It is a professional and in-depth study on ... providing a basic overview of the industry including ... Insulin Needles market analysis is provided for the ...
(Date:5/3/2016)... Ariz. , May 3, 2016  As a ... twice contracted rheumatic fever, which damaged his heart. He ... But by June 2013, Shepherd,s heart was giving ... from death. On June 20, 2013, the ... Total Artificial Heart (TAH-t). Like a heart transplant, the ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... In honor of National ... encouraging people all over the United States to thank a nurse who's made a ... will donate $5 to the American Red Cross of San Diego/Imperial Counties (up to ...
(Date:5/5/2016)... Boston, MA (PRWEB) , ... May 05, 2016 , ... ... stress becomes a constant presence, it can weaken the immune system and increase inflammation, ... Ami B. Bhatt, director of the adult congenital heart disease program at Harvard-affiliated Massachusetts ...
(Date:5/5/2016)... ... May 05, 2016 , ... CURE Media Group ... today announced a new collaboration with Imerman Angels to expand outreach and ... the world. , “Imerman Angels provides an emotional lifeline to patients and families facing ...
(Date:5/5/2016)... ... May 05, 2016 , ... Dermatologic surgeons performed nearly 10 ... and up 27 percent since 2012. , The results of the 2015 ASDS Survey ... increase in skin cancer treatments and the growing popularity of soft-tissue fillers and body ...
(Date:5/5/2016)... , ... May 05, 2016 , ... Liposuction specialist Marcia ... Conference in St. Louis, Missouri at the Marriot St. Louis Airport Hotel. This year’s ... chosen to address the conference about her unique specialization in treating Lipedema. Dr. Byrd ...
Breaking Medicine News(10 mins):